Autoantibody specificities in Lambert-Eaton myasthenic syndrome.
Lang
B
B
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, United Kingdom.
Johnston
I
I
Leys
K
K
Elrington
G
G
Marqueze
B
B
Leveque
C
C
Martin-Moutot
N
N
Seagar
M
M
Hoshino
T
T
Takahashi
M
M
D000918:Antibody Specificity; D001323:Autoantibodies / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D015640:Ion Channel Gating / Q000187:drug effects; D015624:Lambert-Eaton Myasthenic Syndrome / Q000276:immunology*; D010455:Peptides / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D020866:omega-Conotoxin GVIA
D001323:Autoantibodies; D015220:Calcium Channels; D010455:Peptides; D020866:omega-Conotoxin GVIA; D002118:Calcium